Clinical characteristics | Case (n) | Percentage |
---|---|---|
Gender | ||
 Male | 20 | 66.7 |
 Female | 10 | 33.3 |
Age | ||
 Median | 64.0 |  |
 Range | 37–77 |  |
Tumor site | ||
 Fundus | 6 | 20.0 |
 Body | 10 | 33.3 |
 Antrum | 14 | 46.7 |
Hematogenous metastasis | ||
 Yes | 17 | 56.7 |
 No | 13 | 43.3 |
Regimens | Â | Â |
 Pt-3d | 14 | 46.7 |
  FLOT | 11 | – |
  DOS | 3 | – |
 Pt-2d | 16 | 53.3 |
  SOX | 12 | – |
  CAPOX | 3 | – |
  FOLFOX | 1 | – |
 PTX | 5 | 16.7 |
  Paclitaxel | 2 | – |
  PX | 2 | – |
  Nab-paclitaxel | 1 | – |
 CPT-11 | 6 | 20.0 |
  IRIR | 4 | – |
  Irinotecan | 1 | – |
  FOLFIRI | 1 | – |
Treatment pattern | ||
 Pt-3d to CPT-11 | 6 | 20.0 |
 Pt-2d to PTX | 5 | 16.7 |
ORR of 1st-line | ||
 PR | 15 | 50.0 |
 SD | 10 | 33.3 |
 PD | 5 | 16.7 |